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Abstract 
 
Background: Drug abuse is one of the most important public health problems worldwide as in Iran. The aim of 
present study was to determine whether opium addiction can affect bone mineral density or not. 
 
Methods: Fifty opium addicted and 50 non-addicted volunteer men aged between 25-45 were enrolled. The 
subjects with positive history of other osteoporosis risk factors were excluded. The vertebral bone density and 
potential confounders (age, cigarette smoking and body mass index) were measured in all subjects.  
 
Results: Twenty six percent of non-addicted vs. 56% of addicted subjects had vertebral osteopenia. According 
to adjusted ORs, addiction to opium (OR: 3.08, CI95% 1.20-7.92) and age (OR: 1.11 CI95% 1.03-1.20) were 
significantly related to vertebral bone loss. 
 
Conclusion: Opium addicted patients were more susceptible to bone loss than non-addicted individuals. So, 
early screening and conducting prevention programs should be taken into consideration for this high risk group. 
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Introduction 
 
Bone mineral density (BMD) is a good index for evalu-
ating bone status and diagnosis of metabolic bone disor-
ders. Osteoporosis and osteopenia are the most prevalent 
metabolic bone diseases that are characterized by low 
BMD.
1-3 Osteoporosis is an asymptomatic  disease  that  
predisposes the patients to bone fragility and fracture 
after minimal trauma or fall down.
3,4 It is a disturbing 
public health problem because of its consequent morbid-
ity, mortality, medical costs and long term cares.
5,6 
Recent data shows that in Iran, the prevalence of os-
teoporosis and osteopenia in individuals aged 50 and 
above was 36.1% and 43.9% in women, and 24.5% and 
70.8% in men, respectively. In addition, among subjects 
under 50 years, 49.6% of women and 59.6% of men 
have low bone mass.
7 According to the Endocrinology 
and Metabolism Research Center (EMRC) report, two 
million people in Iran are at the risk of fracture. 
The annual cost of hip fractures in Iran is between 
8,000,000 and 16,000,000 US $.
8 These data indicate 
that loss of bone density and its consequent complica-
tions are major public health problem in Iran as other 
developing countries. A study about the burden of 
osteoporosis  in 2004, showed that Disability Adjust-
ed Life Years (DALYs) attributable to osteoporosis is 
36026 among Iranian population (18757 in men and 
17270 in women).
2 
The main risk factors of decreased bone mineral 
density are: age, gender, life style, nutrition, hormonal 
changes and some medical conditions. It has been re-
ported that 20-50% of bone mass changes are related to 
life style. Immobility, smoking, alcohol drinking  and 
low calcium and vitamin D intake are the most im-
portant lifestyle factors that affect BMD.
9 So, the pre-
vention programs that focus on the life style develop-
ment and  screening of high risk groups can play an im-
portant role in the early diagnosis, treatment and de-
creasing of morbidity and complications of the disease. 
Opium abuse is a major public health problem 
worldwide as in our country. It is considered as the 
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most common type of drug abuse in Iran.
10 It is esti-
mated that about 5-9% of Iranian population are ad-
dicted to opium.
11,12 The effect of opium addiction on 
the bone mineral density is not clear. Only one study 
in 1993 showed that chronic heroin abuse is associat-
ed with altered bone metabolism and reduced trabecular 
bone mass.
13 Other studies indicate that chronic con-
sumption of opiates can induce hypogonadim and in-
crease serum level of prolactin.
14-17 Both hypogonadism 
and hyperprolactinemia may lead to osteoporosis.  
So, considering the high prevalence of opium ad-
diction in Iran and the lack of data that reveal the ef-
fect of opium abuse on the BMD, based on review of 
literature, we examined the relationship between 
chronic opiate abuse and bone mass. The confound-
ing roles of the other potential risk factors were also 
considered. 
 
 
Materials and Methods 
 
In this case-control study, we enrolled 50 opium ad-
dicted and 50 non-addicted volunteer men aged be-
tween 25-45 years. All patients were interviewed 
based on the DSM-IV criteria for opium dependency. 
The morphine urine test was conducted in the control 
group. To confirm the inclusion of participants in the 
study, subjects with following diseases or conditions 
were excluded before densitometry: known history or 
evidence of rheumatoid arthritis, thyroid, parathyroid 
or adrenal disease, hepatic or renal failure, metabolic 
bone disease, type I diabetes mellitus, sterility, malab-
sorption, immobility for more than one week and alco-
holism. All remaining subjects signed an informed con-
sent which explained all aspects of study and asked for 
the permission of bone densitometry test. Body mass 
index (BMI) was measured in all subjects. 
BMD was measured once at the lumbar spine (L2-
L4) with dual X-ray absorptiometry using Lunar DPX 
densitometers (Lunar 7164, GE, and Madison, WI). 
The procedure was carried out by a trained operator 
according to the manufacturer’s instruction. Machine 
calibration was done on a daily basis. Daily and 
weekly quality assurance tests were performed as 
recommended by the DXA machine manufacturers. 
For classification of bone marrow densitometry re-
sults, we used World Health Organization criteria 
.According to the criteria, the T- score between -1 to -
2.5 standard deviation was considered as osteopenia 
and T-score≤-2.5 standard deviation was regarded as 
osteoporosis. The normal BMD was defined as hav-
ing T-score≥-1 standard deviation.
18  
The data were entered and analyzed by SPSS17 
software (Version 15, Chicago, IL, USA). In order to 
explore the relationship between opium consumption (as 
the predictor) and the bone marrow density, univariate 
and multiple logistic regression models were applied. 
According to above definition, osteopenia and osteopo-
rosis were categorized as bone loss and entered as de-
pendent variable in the model. Other potential con-
founders (age, cigarette smoking and body mass index) 
were also entered in the model as predictor variables. 
The crude and adjusted OR was reported. P values less 
than 0.05 were considered as significant level.  
 
 
Results 
 
The mean age of addicted and non-addicted groups was 
36.00±6.54 and 35.38±6.7 years respectively. There was 
not any significant difference between the age and histo-
ry of cigarette smoking  in two groups but the mean of 
BMI in addicted group was significantly lower than that 
of non-addicted ones (p=0.002, Table1). 
Table1:  The comparison of studied variables and bone status in opium addicted and contol 
groups. 
P value Non addicted 
N=50 
Opium addicted
N=50 
Variable 
0.64  35.38±6.7  36.00±6.54  Age Mean±SD 
0.002  24.27±3.85  21.96±3.46  BMI Mean±sD 
0.31  34 (61)  37 (77.1)  Cigarrette smoking No. (%) 
0.002 
 
37 (74) 
13 (26) 
 
22 (44) 
28 (56) 
Vertebral BMD frequency (%) 
   Normal 
   Osteopenia 
0.001  1.01±0.12  0.92±0.12  Lumbar measurement Mean±SD 
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According to WHO criteria, 26% of non-addicted 
and 56% of addicted individuals had osteopenia 
which shows the difference between the two groups 
to be statistically significant (p=0.011). None of the 
subjects had osteoporosis. The mean lumbar meas-
urement in opium addicted group was statistically 
lower than non addicted ones.  
To study the confounding effects of cigarette 
smoking, BMI and age on opium addiction and bone 
density relation, the multivariate analysis was per-
formed. According to adjusted ORs, addiction to opi-
um (OR=3.08, CI95% 1.20-7.92) and age (OR=1.11 
CI95% 1.03-1.20) were significantly related to lum-
bar bone loss (Table2). 
 
 
Discussion 
 
The findings of this study indicate that opium addict-
ed individuals are more susceptible to loss of lumbar 
BMD than non-addicted ones. There are some re-
searches about the possible mechanisms of opium 
osteoporosis. Pedrazzoni et al. in 1993 revealed that 
the vertebral bone trabecular mass and bone density 
in individuals with the history of chronic heroine 
abuse are significantly lower than control group. 
They also showed an increased level of serum ionized 
calcium and urine hydroxyproline and decreased level 
of serum LH and PTH in heroin addicted group com-
pared to controls
13 Opium can interact with bone me-
tabolism in different ways: some researches estab-
lished that opium abuse can suppress hypotalamo-
hypophysio-gonadal axis and consequently decreases 
the level of gonadal hormones.
13,19-21 It is well known 
that chronic hypogonadism is a prominent cause of 
osteoporosis in both sexes.
19-21 Hejazian et al. in 2007 
revealed that the level of serum testosterone, LH and 
FSH hormones significantly decrease in opium ad-
dicted group as compared with the control group.
19 In 
2009, Fraser et al. found that in patients who received 
long term opiates to relieve the pain, there is a much 
higher prevalence of hypogonadism in men than in 
women (75% vs. 21%). In their study, osteopenia was 
reported in 50% of men and 21% of women which 
was statistically significant.
14  
Moshtaghi-Kashanian et al. in 2006 showed an in-
creased level of prolactin in concurrent opium and 
cigarette smokers in comparison with cigarette smok-
ers alone (86.96% vs. 41.65%).
15 Other researches 
also reached the same results.
16,22,23 Hyperprolac-
tinemia is one of the well known risk factors for de-
veloping bone loss that is another explanation for in-
creased risk of bone loss and bone fracture in opium 
addicted persons. In addition to indirect effects of 
opium, this substance may also contribute to lowered 
bone mineral density and increased fracture risk by 
directly interfering with bone formation.
19 Inhibition 
of human osteoblastic tissue cultures growth, de-
crease in serum osteocalcin levels and finally  inhibi-
tion of osteocalcin production by osteoblast tissue 
cultures are some direct effects of opium on bone 
formation.
19 
Opium consumption is usually accompanied by 
specific risky life styles such as cigarette smoking, 
low physical activity and poor nutrition. Poor nutri-
tional status among them who are addicted to opium 
is a result of economical problems and loss of appe-
tite. Opium addiction can lead to low dietary intake of 
calcium and phosphor and indirectly makes the indi-
vidual more prone to bone loss. 
Although in our study the cigarette smoking was 
not related to bone loss but there is a growing body of 
evidence that suggest cigarette smoking is a risk fac-
tor for osteoporosis, but the nature of this relationship 
is not clear.
24 Some studies indicate that cigarette 
smoking is a risk factor for osteoporosis and bone 
loss.
25-28 But other studies have found no obvious evi-
dence about the relationship between cigarette smok-
ing and loss of bone density.
19,29,30 
This difference among available data can be due to 
variation in study design, gender of subjects, sample 
size and considering the probable confounding factors 
Table2: Univariate and Multivariable analysis of the studied variables that predicting the bone mineral density.
Adjusted Analysis  Crude Analysis Variables 
P value CI 95% OR P value CI 95%  OR 
0.019  1.20-7.92  3.08  0.003  1.55-8.41  3.62  Opium addiction 
0.74  0.29-2.40  0.83  0.63  0.50-3.09  1.24  Cigarette smok-
ing 
0.003  1.03-1.20  1.11  0.006  1.02-1.17  1.096  Age 
0.121  0.78-1.02  0.89  0.023  0.78-0.98  0.87  BMI 
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(such as BMI). 
We can point to these aspects among the most im-
portant strengths of our study: First, we considered 
some well known factors and medical conditions that 
may influence bone mass as exclusion criteria. Se-
cond, we have carried out our study on male samples 
to set aside female hormonal changes that may affect 
bone mass. Third, we chose the individuals aged be-
tween 25-45 years to avoid a mix up with age related 
bone loss that often occurs above 50 years and finally 
multivariate analysis considered the effect of main 
potential confounders. 
The main limitation of our study was that we did 
not measure the level of gonadal hormones and some 
bone markers such as urine hydroxyproline, calcium, 
phosphor and alkaline phosphatase in our samples. We 
strongly recommend conducting more precise studies 
to measure these bone markers in sera of the subjects. 
Our results suggest that opium addicted patients are 
more susceptible to bone loss than non-addicted indi-
viduals. So, early screening and conducting prevention 
programs should be taken into consideration for this 
high risk group. Without any doubt, further studies to 
explore responsible mechanisms are needed. 
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